Please select an option below to help us tailor your newsletter to best suit your content interests!
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors: Breast, Lung (NSCLC), Colon, Prostate, Bladder, Kidney, Esophagus, Stomach (Gastric), Liver (HCC), Cervical, Endometrial, Ovarian, Skin, Head and Neck (SCCHN), Bladder, Kidney (renal cell), Pancreatic, Rectal, Brain (GBM, glioblastoma)
Stage 4
Phase 2
Open to Enrollment
Following all effecive therapy (late line)
Pemigatinib
FGFR inhibitor
Dan Vaena, MD
Incyte Corporation
FGFR 1,2,3 mutated or FGFR 1,2,3 fusion/translocation
An open-label, multicenter, multinational, phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Breast, Brain (GBM), Head and Neck, Prostate, Kidney (Renal Cell), Melanoma, Ovarian, Endometrial (Uterine), Cervical, Gastric, Pancreatic, Hepatocellular (HCC), Esophageal, lymphoma, sarcoma
Stage 4
Phase 2
Open to Enrollment
Any (provided no curative therapy available)
Neratinib
pan-HER TKI
Lee Schwartzberg, MD
Puma Biotechnologies
HER2 (ERBB2) mutation or HER4 (ERBB4 mutation), or EGFR ex. 18 mutated lung cancer
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVEndometrial, Ovarian, Breast, Lung, Colon, Prostate, Gastric, Esophageal, Cervical, Melanoma, Skin, Pancreas, Pancreatic, Sarcoma, Head and Neck (HNPCC), NSCLC, SCLC, Kidney, Bladder, RCC, Prostate
Stage 4
Phase 1
Open to Enrollment
Late line (post standard therapy)
COM-701, BMS-986207, nivolumab
PVRIG antagonist, anti-TIGIT Ab, PD-1 antibody
Dan Vaena, MD
Compugen, Ltd
PVRL2 high (only for basket cohort)
A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Ovarian, Gastric, Pancreatic, Endometrial, lung, prostate, breast
Stage 4
Phase 1
Open to Enrollment
Late line
OBI-888
Anti-globo-H antibody
Axel Grothey, MD
OBI Pharma
Globo-H overexpression
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVAnal cancer, Pancreatic cancer, PDAC, Cervix, cervical cancer, Gastric cancer, Gastroesophageal cancer, SCLC, Small cell lung cancer, penile, vulvar
Stage 4
Phase 1
Open to Enrollment
2nd or later
PEN-866
HSP-90 inhibitor
Dan Vaena, MD
Tarveda Therapeutics
adenocarcinoma or squamous cell carcinoma